The Latest Cardiac and Vascular News
CARLSBAD, Calif., March 01, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on March 1, 2023 that were approved by the Compensation Committee of its Board of […]
Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company […]
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December […]
heart-1 Clinical Trial of VERVE-101 Ongoing in New Zealand and UK; Data from Dose Escalation Cohorts Expected in the Second Half of 2023 VERVE-201 Progressing Through Preclinical Development with Clinical Initiation Anticipated in 2024 Well-Capitalized with $554.8 Million Supporting Runway into the Second Half of 2025 BOSTON, March 02, 2023 […]
McDermott + Bull Partner Ken Dropiewski interviews Gilde Healthcare General Partner Geoff Pardo in his series, Investor Insights in Life Sciences + MedTech. In the conversations below, Ken and Geoff discuss what venture in MedTech will look like in 2023, what Gilde Healthcare looks for in new investment opportunities, and more.
— System Leverages Next Generation DeepOCT™ Technology and Near Infrared Spectroscopy to Optimize Coronary Stent Placement in the Cardiac Catheterization Lab — — First-in-Human Cases Completed with HyperVue System — BEDFORD, Mass.–(BUSINESS WIRE)–SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery […]
Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile On track to file INDi application to US FDA in Q1 2023 Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of […]
Combined Data From FOURIER and FOURIER-OLE Studies Show Earlier, Longer Use of Repatha Reduces Total CV Events Analysis From Phase 2 OCEAN(a)-DOSE Study Shows Olpasiran Markedly Reduced Lp(a) Concentration Irrespective of Baseline Level Amgen Convenes First LDL-C Action Summit to Help Improve State of Cardiovascular Disease Care in the U.S. […]
The six-month EXCITE-HCM study of 70 patients will study the effects of exercise on electrical activity and blood flow using Vivalink’s medical wearable ECG sensor and cloud data services. CAMPBELL, Calif., March 1, 2023 /PRNewswire/ — UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink‘s Biometrics Data Platform. […]
Fully interoperable smart imaging systems and informatics solutions connect teams in radiology, oncology, cardiology and pathology to enhance clinical confidence and advance precision in diagnosis and treatment Vienna, Austria and Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced its radiology portfolio of […]
